Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion
- 1 March 1990
- journal article
- editorial
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 13 (3) , 257-261
- https://doi.org/10.1007/bf03349555
Abstract
Although somatostatin inhibits a variety of pituitary and non-pituitary hormones, not univocal data on its effects on ACTH release have been reported so far. In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison’s disease, 2 patients previously adrenalectomized for Cushing’s disease, 4 patients with Cushing’s disease and 3 patients with ectopic ACTH syndrome. Plasma ACTH and Cortisol levels were determined after somatostatin (500μg over 60 min) infusion or octreotide (100μg sc) injection. In 5 other patients with Cushing’s disease ACTH and Cortisol responses to CRH (1 μ/kg iv) were evaluated in basal conditions and after octreotide acute administration. In no patients with Addison’s disease any inhibitory influence of somatostatin (Δ % = −21, −25) or octreotide (Δ % = −38 ± 12 vs −39 ± 12 after saline) on plasma ACTH was found. Somatostatin did not significantly inhibit plasma ACTH in the two patients previously adrenalectomized for Cushing’s disease and in 3 patients with Cushing’s syndrome; in other 4 patients with Cushing’s syndrome octreotide did not affect plasma ACTH levels. In 5 patients with Cushing’s disease the plasma ACTH and Cortisol responses to CRH were similar both before (ACTH from 9.9 ± 1.7 pmol/L to 19.4 ± 6.1 pmol/L; Cortisol from 496 ± 43.9 nmol/L to 923 ± 355 nmol/L) and after octreotide injection (ACTH from 8.8 ± 2.4 pmol/L to 19.1 ± 8.2 pmol/L; Cortisol from 510 ± 54.6 nmol/L to 735 ± 220 nmol/L). In conclusion, the acute administration of somatostatin or octreotide is not able to modify ACTH levels in patients with corticotropin hypersecretion either due to hypo-cortisolemic state or consequent to ACTH-secret-ing pituitary or ectopic tumors; moreover, octreotide does not affect the pituitary-adrenal responsiveness to CRH in patients with Cushing’s disease.This publication has 18 references indexed in Scilit:
- Studies on the Conditions Determining the Inhibitory Effect of Somatostatin on Adrenocorticotropin, Prolactin and Thyrotropin Release by Cultured Rat Pituitary CellsNeuroendocrinology, 1989
- The Role of Somatostatin in the Regulation of Anterior Pituitary Hormone Secretion and the Use of Its Analogs in the Treatment of Human Pituitary TumorsEndocrine Reviews, 1988
- Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome.Gut, 1988
- LUNG CARCINOID WITH CUSHING'S SYNDROME: CONTROL OF SERUM ACTH AND CORTISOL LEVELS USING SMS 201–995 (SANDOSTATIN)Clinical Endocrinology, 1988
- Studies on the Mechanism of Action of the Inhibitory Effect of the Somatostatin Analog SMS 201–995 on the Growth of the Prolactin/Adrenocorticotropin-Secreting Pituitary Tumor 7315aEndocrinology, 1986
- The Effect of SMS 201-995, a Long-Acting Somatostatin Analogue, on Anterior Pituitary Function in Healthy Male VolunteersScandinavian Journal of Gastroenterology, 1986
- Effect of hypothalamic neuropeptides on corticotrophin release from quarters of rat anterior pituitary gland in vitroJournal of Endocrinology, 1984
- ACTH Response to TRH and Somatostatin in Nelson's SyndromeHormone and Metabolic Research, 1982
- No inhibition of corticotrophin (ACTH)-hypersecretion in adrenal insufficiency by somatostatinActa Endocrinologica, 1980
- EFFECTS OF GROWTH HORMONE RELEASE-INHIBITING HORMONE AND BROMOCRYPTINE (CB 154) IN STATES OF ABNORMAL PITUITARY-ADRENAL FUNCTIONClinical Endocrinology, 1976